BioCentury | Oct 6, 2020
Product Development

FDA pushing Makena, early drug pricing target, off the market

...Agency action unlikely to affect Covis’ pending $498M takeout of AMAG By Steve Usdin, Washington Editor...
...proposal probably will not affect last week’s proposed acquisition of AMAG by Luxembourg-based specialty pharma Covis...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

...the gene therapy to treat Duchenne muscular dystrophy.Covis to acquire AMAG, marketer of Makena Luxembourg-based specialty pharma Covis...
...million shares at $15, the midpoint of its proposed $14-16 range. BC Staff Veklury, remdesivir (GS-5734) SGT-001 Mesoblast Ltd. Gilead Sciences Inc. Solid Biosciences Covis Beckman...
BioCentury | Jun 6, 2020
Product Development

Failing in master protocol casts fresh doubt on hydroxychloroquine even as WHO restarts trial

Capping a fortnight’s worth of roller-coastering hydroxychloroquine news, a June 4 interim analysis of the University of Oxford’s RECOVERY study found that the malaria drug failed to benefit hospitalized COVID-19 patients. It is the most...
BioCentury | Nov 16, 2018
Company News

Covis gains full rights to ciclesonide drugs from AZ

...ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $350 million. Covis...
...and Zetonna are nasal sprays indicated to treat rhinitis. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Covis Pharma S.a.r.l....
...Business: Inflammation Shannon Lehnbeuter Alvesco, ciclesonide (inhaled) Omnaris, ciclesonide nasal spray Zetonna (Brand), ciclesonid (Generic), Zetonna nasal aerosol (Informal) AstraZeneca plc Covis Pharma S.a.r.l....
BioCentury | Aug 1, 2016
Company News

ANI Pharmaceuticals sales and marketing update

...testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis Pharma S.a.r.l....
...Switzerland) U.S. rights to Nilandron. In 2015, Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX, Oakville, Ontario) acquired Covis’...
BioCentury | Jun 1, 2015
Company News

Covis, Concordia Healthcare deal

...Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for...
...its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l....
BioCentury | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement

...TD Securities Note: Concordia sold subscription receipts. Upon closing of a deal between Concordia and Covis Pharma S.a.r.l....
...terminated, receipt holders will be refunded the subscription price plus interest earned. Concordia is purchasing Covis’...
BioCentury | Mar 16, 2015
Company News

Covis, Concordia Healthcare deal

...Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis...
...formulation of hydroxychloroquine, which is marketed to treat malaria. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) granted Covis...
...rights to commercialize Nilandron and Plaquenil in 2013. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) granted Covis...
BioCentury | Oct 30, 2014
Strategy

The ALS bucket brigade

...symptom onset. The only marketed treatment for the disease is Rilutek riluzole from Sanofi and Covis Pharma S.a.r.l....
...centralized location Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Cedars-Sinai Medical Center , Los Angeles, Calif. Covis Pharma S.a.r.l....
BioCentury | Feb 17, 2014
Company News

Covis, GlaxoSmithKline sales and marketing update

...of $240. The company already markets 0.25 and 0.125 mg strengths. In 2011, GlaxoSmithKline granted Covis...
...U.S. and Puerto Rican rights to commercialize the cardiac glycoside (see BioCentury, Jan. 2, 2012). Covis Pharma S.a.r.l....
Items per page:
1 - 10 of 13
BioCentury | Oct 6, 2020
Product Development

FDA pushing Makena, early drug pricing target, off the market

...Agency action unlikely to affect Covis’ pending $498M takeout of AMAG By Steve Usdin, Washington Editor...
...proposal probably will not affect last week’s proposed acquisition of AMAG by Luxembourg-based specialty pharma Covis...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

...the gene therapy to treat Duchenne muscular dystrophy.Covis to acquire AMAG, marketer of Makena Luxembourg-based specialty pharma Covis...
...million shares at $15, the midpoint of its proposed $14-16 range. BC Staff Veklury, remdesivir (GS-5734) SGT-001 Mesoblast Ltd. Gilead Sciences Inc. Solid Biosciences Covis Beckman...
BioCentury | Jun 6, 2020
Product Development

Failing in master protocol casts fresh doubt on hydroxychloroquine even as WHO restarts trial

Capping a fortnight’s worth of roller-coastering hydroxychloroquine news, a June 4 interim analysis of the University of Oxford’s RECOVERY study found that the malaria drug failed to benefit hospitalized COVID-19 patients. It is the most...
BioCentury | Nov 16, 2018
Company News

Covis gains full rights to ciclesonide drugs from AZ

...ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $350 million. Covis...
...and Zetonna are nasal sprays indicated to treat rhinitis. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Covis Pharma S.a.r.l....
...Business: Inflammation Shannon Lehnbeuter Alvesco, ciclesonide (inhaled) Omnaris, ciclesonide nasal spray Zetonna (Brand), ciclesonid (Generic), Zetonna nasal aerosol (Informal) AstraZeneca plc Covis Pharma S.a.r.l....
BioCentury | Aug 1, 2016
Company News

ANI Pharmaceuticals sales and marketing update

...testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis Pharma S.a.r.l....
...Switzerland) U.S. rights to Nilandron. In 2015, Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX, Oakville, Ontario) acquired Covis’...
BioCentury | Jun 1, 2015
Company News

Covis, Concordia Healthcare deal

...Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for...
...its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l....
BioCentury | Apr 13, 2015
Financial News

Concordia Healthcare proposes private placement

...TD Securities Note: Concordia sold subscription receipts. Upon closing of a deal between Concordia and Covis Pharma S.a.r.l....
...terminated, receipt holders will be refunded the subscription price plus interest earned. Concordia is purchasing Covis’...
BioCentury | Mar 16, 2015
Company News

Covis, Concordia Healthcare deal

...Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis...
...formulation of hydroxychloroquine, which is marketed to treat malaria. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) granted Covis...
...rights to commercialize Nilandron and Plaquenil in 2013. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) granted Covis...
BioCentury | Oct 30, 2014
Strategy

The ALS bucket brigade

...symptom onset. The only marketed treatment for the disease is Rilutek riluzole from Sanofi and Covis Pharma S.a.r.l....
...centralized location Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Cedars-Sinai Medical Center , Los Angeles, Calif. Covis Pharma S.a.r.l....
BioCentury | Feb 17, 2014
Company News

Covis, GlaxoSmithKline sales and marketing update

...of $240. The company already markets 0.25 and 0.125 mg strengths. In 2011, GlaxoSmithKline granted Covis...
...U.S. and Puerto Rican rights to commercialize the cardiac glycoside (see BioCentury, Jan. 2, 2012). Covis Pharma S.a.r.l....
Items per page:
1 - 10 of 13